Medroxyprogesterone Injection and Fosaprepitant: Interaction Details

Brand names
Fosaprepitant
EmendFocinvez
Medroxyprogesterone Injection
Depo-Proveradepo-subQ provera 104Provera +1 more
Same medicines, other forms
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page

A close look at the Medroxyprogesterone Injection and Fosaprepitant interaction:

Share

Share this interaction

Fosaprepitant

Brand names
  • Emend
  • Focinvez

We don't have a drug information page for Fosaprepitant yet. Have a question about Fosaprepitant? Ask a pharmacist, free →

Medroxyprogesterone Injection

Brand names
  • Depo-Provera
  • depo-subQ provera 104
  • Provera
  • Depo-SubQ Provera

What Happens When You Take Medroxyprogesterone Injection With Fosaprepitant

What can happen when they are taken together (rated Major)

Reduced hormonal contraceptive exposure, reduced of hormonal contraceptives and an increased risk of breakthrough bleeding/contraceptive failure

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Taking aprepitant or fosaprepitant together with hormonal contraceptives can lower the exposure to the contraceptive hormones, which may weaken contraceptive efficacy and result in breakthrough bleeding and/or contraceptive failure. Studies have shown that co-administration produces a significant reduction in both the and the minimum concentration of ethinyl estradiol and norethindrone. Patients should be told to rely on an alternative or back-up contraceptive method throughout treatment and for 1 month after the final dose of fosaprepitant or oral aprepitant.231

The Medroxyprogesterone Injection and Fosaprepitant Interaction, Explained

Fosaprepitant (Emend) is given by IV to prevent nausea, often with chemotherapy. It can speed up how your body breaks down some hormones, which may make hormonal birth control work less well. The research behind this was done mostly with pill-type contraceptives (ethinyl estradiol and norethindrone). For medroxyprogesterone shots like Depo-Provera, the concern is more theoretical, but it is still taken seriously.

The main risk is less reliable pregnancy protection, and sometimes breakthrough bleeding. Fosaprepitant's effect can last for a while after the dose. Many care teams suggest using a back-up method of birth control, such as condoms, during treatment and for 1 month after your last dose. Please talk with your pharmacist or doctor about the best plan for you. Don't skip or change any medicine on your own.

Mechanism: Aprepitant/fosaprepitant is a moderate (and ). Labeling reports a significant decrease in and Cmin of ethinyl estradiol and norethindrone. Medroxyprogesterone is largely CYP3A4-metabolized, so reduced exposure is plausible, but the interaction for the injectable is extrapolated (theoretical).

  • Direction: reduced hormonal exposure, potential contraceptive failure or breakthrough bleeding.
  • Onset: delayed. effect may persist after the last dose.
  • Management: advise an effective alternative or back-up contraceptive method during therapy and for 1 month after the last fosaprepitant (or oral aprepitant) dose.

See the 3 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Medroxyprogesterone Injection and Fosaprepitant Interact

The likely mechanism

of -mediated of ethinyl estradiol

How Drug Interactions Work Six short figures, about a minute: how one drug can raise or lower another’s level, or add to or cancel its effect. See how it works 

How to Manage the Medroxyprogesterone Injection and Fosaprepitant Interaction

Your care team usually handles this by adding extra protection rather than changing your shot.

  • Keep your medroxyprogesterone schedule and your fosaprepitant as prescribed unless told otherwise.
  • Use an effective back-up or alternative birth control method during treatment and for 1 month after your last fosaprepitant dose.
  • Tell your pharmacist or prescriber about any breakthrough bleeding or missed periods.
  • Ask your care team which back-up method suits you best, and how your plan may be individualized.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Medroxyprogesterone Injection or Fosaprepitant need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

1 report from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Prescribing information: EMEND intravenous injection, fosaprepitant intravenous injection

    In a study where oral aprepitant 100 mg was administered once daily for 14 days together with an oral contraceptive containing ethinyl estradiol 35 mcg and norethindrone 1 mg, the of ethinyl estradiol fell by 43% and the AUC of norethindrone fell by 8%. In a separate study, a combination contraceptive containing ethinyl estradiol and norethindrone was given daily for 21 days.

    On day 8, patients received oral aprepitant 125 mg, intravenous ondansetron 32 mg, and oral dexAMETHasone 12 mg. On days 9 and 10, oral aprepitant 80 mg/day and dexAMETHasone 8 mg/day were administered, and on day 11 oral dexAMETHasone 8 mg was given alone.

    On day 10, the ethinyl estradiol AUC was reduced by 19%, while the norethindrone AUC was unchanged. Across days 9 through 21, the minimum concentration of ethinyl estradiol declined by as much as 64% and that of norethindrone declined by up to 60%.2

Medroxyprogesterone Injection and Fosaprepitant: Common Questions

How serious is the Medroxyprogesterone Injection and Fosaprepitant interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Medroxyprogesterone Injection and Fosaprepitant interaction managed?

Your care team usually handles this by adding extra protection rather than changing your shot. Keep your medroxyprogesterone schedule and your fosaprepitant as prescribed unless told otherwise. Use an effective back-up or alternative birth control method during treatment and for 1 month after your last fosaprepitant dose. Tell your pharmacist or prescriber about any breakthrough bleeding or missed… Management is individual — always follow your own care team's guidance.

Is there an alternative to taking Medroxyprogesterone Injection with Fosaprepitant?

Use an effective back-up or alternative birth control method during treatment and for 1 month after your last fosaprepitant dose.

Only your prescriber can decide whether a change fits you, so talk with them before changing either medicine.

How quickly could this interaction happen?

The documented onset is "delayed". Effects tend to build up gradually over days to weeks.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

Ask About the Medroxyprogesterone Injection and Fosaprepitant Interaction

Ask in your own words about taking Medroxyprogesterone Injection and Fosaprepitant together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (3)

  1. Product Information: NuvaRing(R) vaginal ring, etonogestrel ethinyl estradiol vaginal ring. Organon & Co. (per FDA), Jersey City, NJ, 2024.
  2. Product Information: EMEND(R) intravenous injection, fosaprepitant intravenous injection. Merck Sharp & Dohme Corp (per FDA), Whitehouse Station, NJ, 2022. DailyMed
  3. Product Information: FOCINVEZ intravenous injection, fosaprepitant intravenous injection. Spes Pharmaceuticals Inc (per FDA), North Brunswick, NJ, 2023. DailyMed
Was this write-up helpful?

Other Serious Interactions of Medroxyprogesterone Injection and Fosaprepitant

Also serious with Fosaprepitant

Also serious with Medroxyprogesterone Injection

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Fosaprepitant

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks. This interaction.
  • UnspecifiedThe timing of this interaction is not well characterized.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.